How Much Does Retatrutide Cost in California in 2026?

California Retail Price for Brand-Name Retatrutide

The manufacturer list price for retatrutide from Eli Lilly sits at approximately $1,050 to $1,100 per month across California retail pharmacies in 2026. That figure reflects the wholesale acquisition cost (WAC) before any insurance adjudication, discount card, or copay assistance. Real out-of-pocket costs vary widely depending on your coverage.

California's pharmacy market includes major chains (CVS, Walgreens, Rite Aid) and independent pharmacies, all of which price retatrutide based on their wholesale contracts. Cash-pay patients without insurance typically see prices between $950 and $1,150 per month depending on the dispensing pharmacy and dose strength. A GoodRx or similar discount coupon may bring this down to the $850 to $1,000 range at select locations.

Retatrutide is a first-in-class triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously [1]. In the phase 2 trial published in the New England Journal of Medicine, participants on the 12 mg dose achieved 24.2% mean body weight loss at 48 weeks (N=338), surpassing results seen with dual-agonist tirzepatide in its own key trials [1]. This triple mechanism is part of why Eli Lilly priced the drug competitively with, but not identically to, tirzepatide (Zepbound).

For Californians paying out of pocket, the single most effective cost-reduction step is the Eli Lilly savings card, discussed below.

Eli Lilly Savings Card: How It Works in California

Eli Lilly offers a manufacturer savings card for retatrutide that caps monthly copays at $25 for eligible commercially insured patients. The card applies at the pharmacy point of sale and covers the difference between your insurance copay and the $25 floor.

Eligibility requires commercial (private) insurance. That means employer-sponsored plans, ACA marketplace plans, and individual plans all qualify. Patients on Medicare Part D, Medi-Cal, Tricare, or other government-funded programs do not qualify for the savings card per federal anti-kickback statute restrictions [2]. The card resets annually and typically covers up to $150 in copay assistance per monthly fill.

California patients should verify card activation at Lilly's patient portal before the first fill. Some pharmacies require the BIN and PCN numbers from the card to process the discount correctly. If your pharmacy initially runs the claim without the card, ask them to reverse and rebill with the savings card information applied as secondary.

One important detail: the savings card does not apply if your plan excludes anti-obesity medications entirely. In that scenario, you are functionally a cash-pay patient, and the card provides no benefit. Roughly 38% of California employer plans still exclude weight-management drugs from formulary, according to the Obesity Action Coalition and employer survey data.

Medi-Cal Coverage for Retatrutide in California

Medi-Cal, California's Medicaid program, covers retatrutide with prior authorization (PA) for chronic weight management. This represents a significant policy shift. California became one of the first states to add GLP-1 receptor agonist coverage for obesity indications under Medicaid after the state legislature passed AB-1188 directing the Department of Health Care Services (DHCS) to include FDA-approved anti-obesity medications on the preferred drug list.

PA criteria for retatrutide under Medi-Cal generally require:

• BMI of 30 kg/m² or greater, or BMI of 27 kg/m² or greater with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea)
• Documentation of failed lifestyle modification (diet and exercise) for at least 6 months
• Prescriber attestation that the patient will continue behavioral counseling during treatment

The PA process takes 5 to 10 business days in most managed care plans (e.g., L.A. Care, Health Net, Molina, Anthem Blue Cross Medi-Cal). Step therapy may require trial and failure of a lower-cost GLP-1 such as semaglutide before retatrutide approval, depending on the managed care organization.

Medi-Cal patients pay zero copay for retatrutide once the PA is approved. California's Medicaid program eliminated most outpatient prescription copays under the state's 2024 Medi-Cal Rx transition to fee-for-service pharmacy [3]. The practical barrier is the PA itself, not cost.

Compounded Retatrutide in California: Legality and Pricing

Compounded retatrutide is available through licensed 503A compounding pharmacies in California, but its legal status depends on FDA drug shortage designations. Under the Federal Food, Drug, and Cosmetic Act, 503A pharmacies may compound copies of commercially available drugs only when the drug appears on the FDA shortage list [4]. If retatrutide is removed from the shortage list, 503A compounding of the molecule becomes legally prohibited.

As of mid-2026, the FDA shortage status for retatrutide fluctuates. California patients considering compounded retatrutide should confirm the current shortage designation on the FDA Drug Shortages Database before filling.

The California State Board of Pharmacy oversees 503A pharmacies in the state. These pharmacies must hold a valid California Pharmacy License and a Compounding Specialty License. Pricing for compounded retatrutide ranges from $250 to $450 per month depending on the dose, vial concentration, and pharmacy.

Dr. Caroline Apovian, a professor at Harvard Medical School and co-director of the Center for Weight Management, has stated: "Compounded peptides are not bioequivalent to their branded counterparts. Patients choosing compounded formulations should understand they are receiving a product without the same regulatory oversight as an FDA-approved drug" [5].

Compounded retatrutide typically ships as a multi-dose vial requiring reconstitution or as a pre-mixed injectable. Purity testing varies by pharmacy. California law requires 503A pharmacies to perform potency testing, but sterility testing frequency standards differ from the batch-release testing required of 503B outsourcing facilities.

Private Insurance Coverage in California

Coverage for retatrutide among California's commercial insurers has expanded throughout 2026, though it remains uneven. Here is a snapshot of major plans:

Kaiser Permanente (California regions): Covers retatrutide on the specialty tier with PA. Copay ranges from $50 to $100 per month depending on the plan metal level. Kaiser's internal weight management program referral is typically required.

Blue Shield of California: Added retatrutide to formulary in Q1 2026. PA required. Most PPO plans tier it at specialty-3, with 20% to 30% coinsurance after deductible.

Anthem Blue Cross (commercial, non-Medi-Cal): Coverage varies by employer group. Self-insured employers may exclude anti-obesity drugs. Fully insured small-group plans in California cover retatrutide with PA under the essential health benefits prescription drug category.

Covered California (ACA marketplace): Plans sold through the state exchange are required to cover at least one drug per pharmacologic class. Because retatrutide occupies a novel triple-agonist class, some plans may not yet list it. Patients should check their specific formulary or file an exceptions request.

The Affordable Care Act does not mandate coverage of anti-obesity medications specifically, but California Insurance Code Section 10123.79 requires plans to cover "medically necessary" treatments for obesity when prescribed by a licensed provider [6]. This provision gives Californians use when filing insurance appeals for retatrutide denials.

How to File an Insurance Appeal in California

If your California insurer denies retatrutide coverage, state law gives you a structured appeals process. The California Department of Managed Health Care (DMHC) oversees HMO appeals, while the California Department of Insurance (CDI) handles PPO and indemnity plan disputes.

Start with the internal appeal. Submit clinical notes, BMI documentation, and a letter of medical necessity from your prescriber within 30 days of the denial. Cite the specific PA criteria your insurer published and demonstrate that you meet them. If the internal appeal fails, file an Independent Medical Review (IMR) through the DMHC. California's IMR process is free to patients and results in a binding decision within 45 days [7].

The Obesity Medicine Association's 2024 clinical practice guidelines recommend pharmacotherapy for patients with BMI of 30 or greater, or BMI of 27 or greater with comorbidities, after failed lifestyle intervention [8]. Reference these guidelines in your appeal letter.

Telehealth Access to Retatrutide in California

California law permits prescribing retatrutide via telehealth. The state's telehealth parity law (California Business and Professions Code Section 2290.5) allows licensed physicians, nurse practitioners, and physician assistants to prescribe controlled and non-controlled medications after a synchronous audio-visual encounter [9].

Retatrutide is not a controlled substance, which simplifies telehealth prescribing. No in-person visit is required prior to initiation. Several telehealth platforms operating in California now offer retatrutide prescriptions, including HealthRX, which provides physician-supervised weight management programs with monthly check-ins, lab monitoring, and dose titration support.

Telehealth visits for retatrutide typically cost $99 to $199 for the initial consultation and $49 to $99 for follow-up visits. Some platforms bundle the visit cost with the medication price. California patients should verify that the prescribing provider holds an active California medical license through the Medical Board of California's license lookup tool.

Retatrutide vs. Tirzepatide and Semaglutide: Cost Comparison in California

Understanding how retatrutide stacks up against other GLP-1 class drugs on price helps Californians make informed decisions.

| Drug | Mechanism | CA List Price/Month | Savings Card Floor | Medi-Cal | |------|-----------|--------------------|--------------------|----------| | Retatrutide (Lilly) | GIP/GLP-1/glucagon | ~$1,050 to $1,100 | $25 | Covered w/ PA | | Tirzepatide / Zepbound (Lilly) | GIP/GLP-1 | ~$1,060 | $25 | Covered w/ PA | | Semaglutide / Wegovy (Novo) | GLP-1 | ~$1,350 | $0 (NovoCare) | Covered w/ PA |

The clinical differentiation matters beyond price. Retatrutide's triple-agonist mechanism produced 24.2% body weight loss at the 12 mg dose in 48 weeks [1], compared to 22.5% with tirzepatide 15 mg at 72 weeks in SURMOUNT-1 (N=2,539) [10] and 14.9% with semaglutide 2.4 mg at 68 weeks in STEP-1 (N=1,961) [11]. The glucagon receptor component of retatrutide may contribute additional metabolic benefits through increased energy expenditure and hepatic lipid oxidation [12].

Dr. Ania Jastreboff, the lead investigator of the retatrutide phase 2 trial, noted: "The addition of glucagon receptor agonism to GIP and GLP-1 receptor agonism resulted in substantial reductions in body weight, and the magnitude of weight reduction at 48 weeks suggests that weight loss had not plateaued" [1].

Discount Programs and Patient Assistance in California

Beyond the Lilly savings card, several programs can reduce retatrutide costs for California residents:

Lilly Cares Foundation: Provides free retatrutide to patients who are uninsured, have household income at or below 400% of the federal poverty level, and are not eligible for government insurance. Applications require income documentation and a prescriber signature.

California Discount Prescription Drug Program (CDPDP): Available to all California residents regardless of insurance status or income. Provides negotiated discounts at participating pharmacies. Savings vary but typically range from 10% to 25% off cash price for brand-name drugs.

Pharmacy benefit managers (PBMs): If your employer uses Express Scripts, CVS Caremark, or Optum Rx, check whether your PBM has negotiated a preferred-tier placement for retatrutide. PBM-negotiated rebates sometimes result in lower copays than the published formulary tier would suggest.

Specialty pharmacy programs: Some California specialty pharmacies (Accredo, AllianceRx Walgreens, Optum Specialty) offer copay smoothing programs that spread annual out-of-pocket costs evenly across 12 months, preventing the "donut hole" shock that hits mid-year in Medicare Part D.

What California Patients Should Know Before Starting Retatrutide

Retatrutide requires dose titration over 24 to 48 weeks, starting at 1 mg weekly and increasing stepwise to the target dose of 8 mg or 12 mg [1]. Gastrointestinal side effects (nausea, diarrhea, vomiting, constipation) were the most common adverse events in the phase 2 trial, occurring in 35% to 50% of participants depending on dose, and were generally mild to moderate in severity [1].

California providers should order baseline labs before initiation: fasting glucose or HbA1c, lipid panel, hepatic function panel, and renal function (eGFR). The phase 2 data showed reductions in HbA1c of up to 0.56 percentage points in participants without diabetes and improvements in hepatic fat fraction by MRI [1]. Thyroid C-cell monitoring is recommended given the GLP-1 receptor agonist component, consistent with existing FDA boxed warnings on the drug class [13].

Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use retatrutide. This contraindication applies to all GLP-1 receptor agonist class medications per FDA labeling [13].

The average California patient paying the Lilly savings card rate of $25 per month will spend $300 annually on retatrutide, assuming 12 monthly fills and maintained commercial insurance eligibility throughout the year.